Insomnia is a significant health and quality of life concern for older adults, with up to half of all adults over the age of 65 experiencing insomnia symptoms. In a new study, researchers in the Penn ...

The FDA approved Zepbound (tirzepatide) as the first prescription medication specifically for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. People taking Zepbound lost an ...

A new study from Penn State University found that older adults who experience symptoms of insomnia and/or use sleep medications face a substantially higher risk of developing disabilities that affect ...

At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists in obstructive sleep apnea (OSA ...

Nonrestorative sleep is linked to increased risk for major adverse cardiac and cerebrovascular events, especially in adults ...

Older adults with long-term benzodiazepine receptor agonist use and insomnia diagnosis had significant improvements in sleep outcomes. HealthDay News — A mailed knowledge mobilization and behavior ...

Sleeping medications taken by millions could lead to disabilities down the line, a new study suggests. Researchers from Penn State University and Taipei Medical University analyzed five years of data ...

On average, 40% of Louisiana adults reported sleeping less than seven hours in a 24-hour period, according to America's Health Rankings analysis of the CDC's 2022 Behavioral Risk Factor Surveillance ...

In this survey, 83% reported that they would “definitely” or “mostly” want to know if they had sleep apnea. Researchers found differences in some responses based on age, sex, race/ethnicity and sleep ...

The Food and Drug Administration (FDA) gave the green light to the the first-ever medication for obstructive sleep apnea (OSA). The newly approved drug, Zepbound (tirzepatide), targets adults with ...